Is there a role for oral anticoagulant therapy in patients with peripheral arterial disease?

Current Drug Targets - Cardiovascular and Haematological Disorders

Volumn 4, Issue 3, 2004, Pages 269-273

  Cosmi, B ^a   Palareti, G ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Anticoagulants; Arterial occlusive disease; Aspirin; Atherosclerosis; Peripheral vascular disease; Platelet aggregation inhibitors; Randomized controlled trials; Vascular surgical procedures; Warfarin

Indexed keywords

4 HYDROXYCOUMARIN DERIVATIVE; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; CLOPIDOGREL; DICOUMAROL; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PROTHROMBIN; TICLOPIDINE; VITAMIN K GROUP; WARFARIN;

ANTICOAGULANT THERAPY; ARTERY DISEASE; ATHEROSCLEROSIS; BLEEDING; BYPASS SURGERY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DRUG MECHANISM; HEMATOMA; HUMAN; INTERMITTENT CLAUDICATION; INTERNATIONAL STANDARD UNIT; KINESIOTHERAPY; LIMB ISCHEMIA; MORBIDITY; MORTALITY; OCCLUSIVE CEREBROVASCULAR DISEASE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL VASCULAR DISEASE; REVIEW; RISK REDUCTION; VEIN BYPASS; VEIN OCCLUSION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ARTERIAL OCCLUSIVE DISEASES; CARDIOVASCULAR DISEASES; EXTREMITIES; HUMANS; INTERMITTENT CLAUDICATION; ISCHEMIA; PERIPHERAL VASCULAR DISEASES; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS; VASCULAR SURGICAL PROCEDURES;

EID: 4444302313     PISSN: 15680061     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568006043336005     Document Type: Review

References (28)

1. Stoffers, H.E., Rinkens, P.E., Kester, A.D., Kaiser, V., Knottnerus, J.A. The prevalence of asymptomatic and unrecognized peripheral arterial occlusive disease. Int. J. Epidemiol., 1996, 25, 282-290.
2. Jelnes, R., Gaardsting, O., Hougard Jensen, K., Baekgaard, N., Tonnesen, K.H., Schoeder, T. Fate in intermittent claudication: outcome and risk factors. Br. Med. J. (Clin. Res. Ed.), 1986, 293, 1137-1140.
3. Leng, G.C., Fowkes, F.G.R., Lee, A.J., Dunbar, J., Housley, E., Ruckley, C.V. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ, 1996, 313, 1440-1444.
4. Balkau, B., Vray, M., Eschwege, E. Epidemiology of peripheral arterial disease. J. Cardiovasc Pharmacol., 1994, 23, Suppl. 3:S8-16
5. Criqui, M.H., Langer, M.D., Fronek, A., Feigelson, H.S., Klauber, M.R., McCann, T.J., Browner, D. Mortality over a period of 10 years in patients with peripheral arterial disease. New Engl. J. Med., 1992, 326, 381-386.
6. Fuster, V., Badimon, L., Badimon, J.J., Chesebro, J. The pathogenesis of coronary artery disease and the acute coronary syndromes. N. Engl. J. Med., 1992, 326, 310-318.
7. Jelnes, R., Gaardsting, O., Hougaard Jensen, K., Backgaard, N., Tonnesen, K.H., Schroeder, T. Fate in intermittent claudication: outcome and risk factors. BMJ, 1986, 293, 1137-1140.
8. Donnelly, R., Yeung, J.M. Management of intermittent claudication: the importance of secondary prevention. Eur. J. Vasc. Endovasc Surg., 2002, 23, 100-107.
9. Cosmi, B., Conti, E., Coccheri, S. Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. Cochrane Database Syst. Rev., 2003, (1): CD001999.
10. Dettori, A.G., Pini, M., Moratti, A., Paolicelli, M., Basevi, P., Quintavalla, R., Manotti, C., Di Lecce, C. Acenocoumarol and pentoxifylline in intermittent claudication. A controlled clinical study. The APIC Study Group. Angiology, 1989, 40, 237-248.
11. De Smit, P., van Urk, H. The effect of long term treatment with oral anticoagulants in patients with peripheral vascular disease. Arterielle Verschlusskrankheit and blutgerinnung, 1987, XXX Hamburger Symposion uber Blutgerinnung: 211-217
12. Antonicelli, R., Sardina, M., Scotti, A., Bonizzoni, E., Paciaroni, E. on behalf of the CAP study group.Randomized trial of the effects of low-dose calcium-heparin in patients with peripheral arterial disease and claudication. Am. J. Med., 1999, 107, 234-239
13. Blaisdell, F.W., Steele, M., Allen, R.E. Management of acute lower extremity arterial ischemia due to embolism and thrombosis. Surgery 1978, 84, 822-834.
14. De Smit, P., van Urk, H. Dutch oral anticoagulation trial. Act. Chir. Austr., 1992, 24, 5-7.
15. Antithrombotic Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I. Prevention of death, myocardial infarction, and stroke by prolonged anti-platelet therapy in various categories of patients. BMJ, 1994, 308, 81-106.
16. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis or randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002, 324, 71-86.
17. CAPRIE Steering Committee, A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 1996, 348, 1329-1339.
18. TASC Working Group. Management of peripheral arterial disease (PAD). J. Vasc. Surg., 2000, 31, s205-s226.
19. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy II: maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ, 1994, 308, 159-168.
20. Franks, P.J., Sian, M., Kenchington, G.F., Alexander, C.E., Powell, J.T. Aspirin usage and its influence on femoro-popliteal vein graft patency. The Femoro-popliteal Bypass Trial Participants. Eur. J. Vasc. Surg., 1992, 6:185-188.
21. Kretschmer, G., Wenzl, E., Piza, F., Polterauer, P., Ehringer, H., Minar, E., Schemper, M. The influence of anticoagulant treatment on the probability of function in femoro-popliteal vein bypass surgery: analysis of a clinical series (1970 to 1985) and interim evaluation of a controlled clinical trial. Surgery, 1987, 102, 453-459.
22. Kretschmer, G., Wenzl, E., Schemper, M., Polterauer, P., Ehringer, H., Marcosi, L., Minar, E. Influence of postoperative anticoagulant treatment on patient survival after femoropopliteal vein bypass surgery. Lancet, 1988, 1: 797-799.
23. Kretschmer, G., Herbst, F., Prager, M., Sautner, T., Wenzl, E., Berlakovich, G.A., et al. A decade of oral anticoagulant treatment to maintain autologous vein grafts for femoropopliteal atherosclerosis. Arch. Surg., 1992, 127, 1112-1115.
24. Arfvidson, B., Lundgren, F., Drott, C., Schersen, T., Lundholm, K. Influence of coumarin treatment on patency and limb salvage after peripheral arterial reconstructive surgery. Am. J. Surg., 1990, 159, 556-560.
25. Dutch Bypass Oral anticoagulants or Aspirin (BOA) study group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet, 2000, 355, 346-351.
26. Johnson, W.C., Williford, W.O. and members of the Department of Veterans Affairs Cooperative Study. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomised study. J. Vasc. Surg., 2002, 35, 413-421.
27. Schneider, E., Brunner, U., Bollinger, A. Medikamentöse Rezidivprophylaxe nach femoropoplitealer Arterienrekonstruktion. Angio., 1979, 2, 73-77.
28. Sarac, T.P., Huber, T.S., Back, M.R., Ozaki, C.K., Carlton, L.M., Flynn, T.C., Seeger, J.M. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. J. Vasc. Surg., 1998, 28, 446-457.